Mackenzie Financial
CYTK icon

Mackenzie Financial’s Cytokinetics CYTK Stock Holding History

Mackenzie Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,059
Closed -$328K – 1610
2024
Q2 		$328K Hold
6,059
– – ﹤0.01% 1137
2024
Q1 		$425K Hold
6,059
– – ﹤0.01% 1057
2023
Q4 		$506K Buy
+6,059
New +$219K ﹤0.01% 995
2023
Q3 		– Sell
-6,059
Closed -$202K – 1498
2023
Q2 		$202K Buy
+6,059
New +$224K ﹤0.01% 1336
2023
Q1 		– Sell
-5,139
Closed -$235K – 1541
2022
Q4 		$235K Sell
5,139
-271
-5% -$11.7K ﹤0.01% 1177
2022
Q3 		$262K Sell
5,410
-54,171
-91% -$2.61M ﹤0.01% 1141
2022
Q2 		$2.34M Buy
+59,581
New +$2.4M ﹤0.01% 687

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Mackenzie Financial's CYTK Position: Q3 2024 in Review

Mackenzie Financial sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 6,059 shares — an estimated $328K sold.

Mackenzie Financial first reported a position in CYTK in Q2 2022 and held it in 7 quarters. The position peaked at $2.34M in Q2 2022. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Mackenzie Financial reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
  • Mackenzie Financial sold 6,059 Cytokinetics shares in Q3 2024, an estimated $328K.
  • Mackenzie Financial first reported a position in Cytokinetics in Q2 2022 and held it in 7 quarters.
  • Mackenzie Financial's Cytokinetics position peaked at $2.34M in Q2 2022.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Mackenzie Financial's 13F filing for Q3 2024, filed 13 Nov 2024.